



## STANFORD MATERNAL AND CHILD HEALTH RESEARCH INSTITUTE

### Stanford Pediatric Inflammatory Bowel (IBD) and Celiac Disease Research Awards Program

#### Full Proposal Policy

#### ELIGIBILITY

The Stanford Pediatric IBD and Celiac Disease Research Awards Program aims to spark innovative and transdisciplinary research and develop new treatments to improve the lives of all children with IBD and celiac disease for generations to come. Through this mechanism we can harness the expertise of scientists already in place across Stanford and pivot their work toward pediatric disease and push research in novel directions to benefit children. The research awards will help fuel early-stage, high-risk, high-reward projects not yet ready for NIH or other government funding.

Research must be primarily related to maternal and child<sup>1</sup> health and proposals should demonstrate a clear potential for the research to generate robust preliminary data for future applications to external funding agencies

The awards will provide up to 2 years of funding to support a wide range of scientific approaches with the potential to advance our understanding of pediatric IBD and celiac disease including but not limited to the following areas:

- Basic and translational research of disease mechanisms, therapeutic strategies, or treatment response in the areas of epithelial biology, microbiology, immunology, enteric nervous system.
- Development of novel technologies to advance IBD research, diagnosis or evaluation, disease monitoring, treatments, or disease/response prediction (biomedical or chemical engineering, computer science).
- Clinical research of novel treatment strategies or impactful health services, epidemiologic, outcomes, or health care disparities research.

- Computational or systems biological approaches to advance understanding of disease mechanisms, treatment targets, or treatment response.

#### FULL PROPOSAL APPLICATION

**Cover Page (using format provided)**

**Lay Summary: 300 words or less**

**Budget (*attached separately as an excel sheet using template provided and included in PDF application*)**

#### Research Proposal:

- Concise description of the project aims, hypothesis, background, preliminary studies (if available), study design and methods, potential limitations, research team expertise and capabilities, research timeline, multi-year budget and IRB approval letter.
- Proposals should include a plan for statistical analyses and a brief description of sample size and statistical power calculations.
- Proposals should clearly articulate the relevance to pediatric IBD and celiac disease and potential for patient impact.
- The proposal should be a maximum six pages text, not including references, and no more than five additional pages of attachments or appendices.
- For all members of the research team submit: NIH Biosketch and Other Support Page.

#### IRB Approval

It is strongly encouraged that you submit your IRB application *prior* to the MCHRI application submission deadline *and* the IRB review meeting date stated in the MCHRI application. If there is an approval letter, it must

---

<sup>1</sup> "Child" or "Children" refers to the expectant mother, oocyte, zygote, embryo, fetus, infant, child and adolescent.

be attached with the application. If approved for funding, the award cannot commence (fund transfer) without the approved protocols. For more information, please see:

<http://humansubjects.stanford.edu/>

### **Biostatistical Consultation**

A biostatistical consult is *required* for all human-based studies and those with power calculations.

As part of a partnership with the Stanford Quantitative Sciences Unit (QSU), MCHRI grant applicants may request services as needed to support the success of their research project (*most services at no charge to the investigator*). Their expertise is available for consultation, the development of grant proposals, and implementation of funded projects. Click [here](#) to submit a request directly to the QSU. Request QSU consults no later than 4 weeks prior to submission deadline.

### **Patient Oriented Research at SCH**

Studies involving patients at Stanford Children's Health (SCH) must contact the SCH Clinical Research Support Office *early in the study design phase* by emailing [crso@stanfordchildrens.org](mailto:crso@stanfordchildrens.org) to ensure hospital units involved can assess feasibility and resource requirements are taken into consideration, including hospital costs. Studies that would occur at SCH without CRSO consultation will not be reviewed or may be asked to resubmit in the next cycle.

### **AWARD**

*Up to \$100,000 / year* for up to two years. Total award of **\$200,000**. Should there be a carryforward balance of greater than twenty-five percent, the funds transfer will be held at the discretion of MCHRI until the balance has been expended.

Unexpended funds will be returned after the performance period (see No-Cost Extensions below).

*Award may be used for:*

- Research personnel (undergraduate or graduate students, post-doctoral fellows,\* research assistants, associates, or faculty)
- PI salary
- Computer software (must be justified), supplies or other materials/ services relevant to the project
- Travel, symposia, or seminars which are an integral part of the proposal

*\*If a substantial portion of the budget will be used to support a post-doctoral fellow, please consider the Stanford Pediatric Inflammatory Bowel (IBD) and Celiac*

*Disease Post-doctoral Fellow Awards.*

*Award may NOT be used for:*

- Student tuition or fees
- Membership dues, journal subscriptions, books
- Poster Presentations or abstract submissions
- Office supplies, computer equipment, software, or accessories for office or administrative use
- ITCC communications
- Any other indirect research costs

### **NO-COST EXTENSIONS**

*Requests must be submitted at least thirty (30) days prior to the end date on the award letter.* Requests are considered on a case-by-case basis. Not all requests are approved. Only one extension is granted per project.

### **SELECTION PROCESS**

Proposals are reviewed by the Pediatric IBD and Celiac Disease review panel. Assessments will be based on the significance, innovation and approach of the proposed research; research environment and investigator team; relevance and potential impact of the research on pediatric IBD and celiac disease.

### **AWARDEE RESPONSIBILITIES**

The PI will take responsibility for the research idea, development methods, supervision and conduct of the study in addition to the following:

- Member of MCHRI, keep Stanford Medicine Profile (formerly-CAP) updated, and utilize "Permit PubMed Import" feature.
- Submit reports in a timely manner, including an annual Progress Report, and a Final Progress Report within 30 days of the award end date.
- Provide updates in all Progress Reports on funding status from external and/or internal sources.
- Submit progress reports for up to 3 years following the award end date that will include information about grants submitted, publications, employment, and new research funding resulting from this award.
- Present the results of their research when asked.
- Acknowledge the research support in all publications, abstracts, presentations, press releases, and inventions resulting from this award as follows:

*"The project described in this publication was supported by the Stanford Pediatric Inflammatory*

*Bowel Disease (IBD) and Celiac Disease Research Awards Program.”*

Award recipients who have not acknowledged the Stanford Pediatric Inflammatory Bowel Disease (IBD) and Celiac Disease Research Awards Program are not eligible for future awards sponsored by the MCHRI.

## **TERM OF AWARD**

All awardees are limited to a single award of up to 2 years. Should there be a change in the awardee's role that significantly alters their ability to carry out their responsibilities, the award will be forfeited prior to the

completion of the term. However, if there have been unusual occurrences then the awardee may request a deferral or leave of absence from the award; this request will be adjudicated by the Director of the Center for Pediatric IBD and Celiac Disease. If a deferral is approved, the end date of this award will be adjusted accordingly by MCHRI administration.

## **CONTACT**

Kim Stern  
[kstern01@stanford.edu](mailto:kstern01@stanford.edu)  
650-724-0279